Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health, Inc. director Myrtle S. Potter reported an open-market sale of Common Stock. She sold 1,556 shares on June 22, 2026 at an average price of $131.16 per share. After this transaction, she directly holds 20,971 Guardant Health shares.
Guardant Health director Roberto Mignone reported routine equity compensation activity, exercising restricted stock units (RSUs) into common shares. On May 21, 2026 and June 21, 2026, RSU conversions of 264 shares each delivered a total of 528 common shares at a stated price of $0.00 per share.
After these transactions, Mignone directly held 9,482 shares of Guardant Health common stock and 7,392 RSUs. Footnotes explain that the RSU award was granted on November 8, 2024 and vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported routine equity compensation activity. On June 17, 2026, he exercised 4,203 Restricted Stock Units into the same number of common shares following full vesting tied to the 2026 Annual Meeting of Stockholders.
He also received a new grant of 2,711 Restricted Stock Units that will vest in full on the one-year anniversary of the grant date, June 17, 2026, or on the date of Guardant Health’s next annual meeting of stockholders, whichever is earlier. Following these transactions, Musa directly holds 12,999 shares of common stock and 2,711 Restricted Stock Units, with no shares sold.
Guardant Health director Myrtle S. Potter reported routine equity compensation activity. On June 17, 2026, she exercised 4,203 Restricted Stock Units, acquiring the same number of common shares and bringing her direct common stock holdings to 22,527 shares. A prior restricted stock unit award vested in full on the 2026 Annual Meeting date. She also received a new grant of 2,711 Restricted Stock Units, which will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Roberto Mignone reported routine equity compensation activity. On June 17, 2026, he exercised restricted stock units covering 4,203 shares of Common Stock, bringing his direct Common Stock holdings to 8,954 shares after the transaction.
On the same date, he received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of Common Stock. According to the footnotes, the RSU award that generated the 4,203 shares vested in full on the date of the 2026 Annual Meeting of Stockholders, while the new 2,711-unit award will vest in full on the earlier of the one-year anniversary of its June 17, 2026 grant date or the Company’s next annual meeting of stockholders.
Guardant Health director Steve E. Krognes reported equity compensation activity. On June 17, 2026, 4,203 Restricted Stock Units fully vested in connection with the company’s 2026 Annual Meeting of Stockholders and were converted into an equal number of shares of common stock.
Following this derivative exercise, Krognes held 14,425 shares of Guardant Health common stock directly. On the same date, he also received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of common stock that will vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting.
Guardant Health, Inc. director Meghan V. Joyce reported the vesting and settlement of a restricted stock unit award into common stock. On June 17, 2026, coinciding with the company’s 2026 Annual Meeting of Stockholders, 4,203 restricted stock units converted into 4,203 shares of common stock at no exercise price. Following this compensation-related transaction, Joyce directly holds 15,386 shares of Guardant Health common stock, and no open-market purchases or sales were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported compensation-related equity activity on June 17, 2026. He exercised vested restricted stock units to acquire 4,435 shares of Common Stock at a conversion price of $0.00 per share and received a new grant of 2,711 restricted stock units. Following these transactions, one reported line shows direct ownership of 5,074 Common Stock shares and 2,711 restricted stock units, reflecting routine vesting and grants rather than open-market trading.
Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity. On June 17, 2026, Gadde exercised restricted stock units covering 4,203 shares of Common Stock, increasing direct holdings to 28,517 shares. On the same date, Gadde also received a new award of 2,711 restricted stock units that will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Ian T. Clark reported equity compensation activity tied to the 2026 Annual Meeting of Stockholders. A previously granted restricted stock unit (RSU) award vested in full on June 17, 2026 and was exercised into 5,092 shares of common stock, bringing indirect holdings in a family trust to 8,067 shares.
Clark also received a new grant of 2,711 RSUs on June 17, 2026. These RSUs convert into the same number of common shares and are scheduled to vest in full on the one-year anniversary of the grant date or on the date of Guardant Health’s next annual stockholder meeting, whichever occurs earlier. All reported transactions are acquisitions related to awards rather than open-market buying or selling.